Recognizing that CF is more than just a lung disease and understanding that modulator therapies may influence the progression of pulmonary disease necessitates prospective clinical studies to examine the impact of novel CFTR modulators on various CF-related complications, including CFLD. The gene discussed is CFTR; the disease is lung disorder.